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ANGIOGENESIS IS THE FORMATION of new blood vessels from preexisting blood vessels. These preexisting blood vessels are quiescent and covered with a basement membrane that is composed of laminin, collagen (type IV), and tenascin. This environment inhibits endothelial cell migration. It is thought that angiogenesis is initiated upon signaling by growth factors such as vascular endothelial growth factor (VEGF) or by injury that stimulates endothelial cells to secret molecules that dissolve the basement membrane of preexisting blood vessels (8) . Endothelial cells in preexisting blood vessels are then exposed to different matrix molecules such as collagen type I and fibronectin. Contrary to the function of the basement membrane of preexisting blood vessels, these new matrixes trigger endothelial cell morphogenesis and migration. These are crucial for the formation of new capillary networks, an early stage of angiogenesis, which involves transition of endothelial precursor cells to a spindle-shape morphogenesis in combination with alignment into precapillary cord-like structures (21, 39) . Among the new extracellular matrix molecules that endothelial cells encounter in the angiogenic environment, collagen type I is a prominent component of most tissue stroma and is considered to be one of the strong proangiogenic factors (37) . Collagen I also plays a significant role in vasculogenesis, another type of vascular morphogenesis, which represents de novo assembly of endothelial cells into tube networks (9) . Collagen I provokes endothelial cells in culture to undergo marked shape changes that closely imitate vascular morphogenesis (39) . Here we employed in vitro models of vascular morphogenesis, tube formation, to determine the mechanism by which collagen I controls the assembly and organization of endothelial cells into new blood vessels.
Glycogen synthase kinase 3␤ (GSK3␤) is a key regulator of numerous signaling pathways including those involving G-protein-coupled receptors and the cellular response to Wnt signaling (10) . GSK3␤ is involved in a variety of cellular processes including glycogen metabolism, insulin signaling, cell proliferation, apoptosis, neuronal function, and embryonic development (15, 30) . Given the multiple processes regulated by GSK3␤, it is not surprising that GSK3␤ has been implicated in various diseases such as diabetes, cancer, bipolar disorder, and Alzheimer disease. The function of GSK3␤ in endothelial cells, however, is not well understood. Skurk et al. (33) have shown that the GSK3␤/␤-catenin axis promotes angiogenesis through activation of VEGF signaling in endothelial cells. Yao et al. (42) recently showed that tissue kallikrein promotes neovascularization, restores regional blood flow, and improves cardiac function via the Akt-GSK3␤ pathway. In addition, Hoang et al. (19) showed that inhibition of GSK3␤ improves angio-architecture and lumen formation, which is important for normalization of abnormal blood vessels. Considering that the pathological conditions such as tumor progression increase structural and functional abnormalities of blood vessels to fuel disease progression and attenuate response to chemotherapies (4) , this study suggests that inhibition of GSK3␤ could be a novel strategy to fight cancer by inducing structurally and functionally normal vasculature.
Here we reveal that GSK3␤ is a key player in collagen I-induced endothelial cell migration and cord formation. More interestingly, we found that protein kinase D (PKD) regulates cord formation through the regulation of GSK3␤ activity. Further studies revealed that GSK3␤ regulates trafficking of integrin ␣ 2 ␤ 1 , one of the receptors for collagen I, through a Rab11-dependent pathway. Therefore, our results provide a novel link between a PKD-GSK3␤-Rab11-integrin ␣ 2 ␤ 1 pathway and endothelial cell morphogenesis.
MATERIALS AND METHODS

Cells and Reagents
Human umbilical vein endothelial cells (HUVEC) were purchased from Lonza and were maintained in EBM-2 endothelial cell growth medium (Lonza) supplemented with EGM-2 SingleQuot kit (Lonza) that includes growth factors, cytokines, and other supplements. Antiphospho-GSK3␤, anti-GSK3␤, anti-phospho-PKD, anti-PKD, antiphospho-Akt, anti-Akt, anti-phospho-S6K1, anti-S6K1, anti-phosphoERKs, and anti-tubulin antibodies were obtained from Cell Signaling Technology. Anti-GSK3␣/␤, anti-PKC␣, and anti-PKC␤I antibodies were purchased from Santa Cruz Biotechnology. Function-blocking anti-integrin ␣ 1, anti-integrin ␣2, anti-integrin ␣v␤3, anti-integrin ␣6, and anti-integrin ␤4 antibodies were obtained from Chemicon. The anti-integrin ␣1 and anti-integrin ␣2 antibodies used for fluorescenceactivated cell sorting analysis were from Chemicon and BD Biosciences. Anti-integrin ␣2 antibodies used for immunofluorescence were obtained from Chemicon. Collagen type I was purchased from BD Biosciences. PD184352, polybrene, and anti-actin antibody were from Sigma. Go6976 was from Calbiochem. LY294002, U0126, SB216763, and SB415286 were purchased from Enzo Life Sciences.
Plasmids
Lentiviral packaging (⌬8.9) and envelope plasmids were a generous gift from Dr. Andrew L. Kung (Dana-Farber Cancer Institute, MA) and Dr. David Baltimore (California Institute of Technology, CA). The plasmids pcDNA3-GSK3␤-WT, pcDNA3-GSK3␤-K85A, and pcDNA3-GSK3␤-S9A were generously provided by Dr. James R. Woodgett (University of Toronto, Canada). GSK3␤-WT and mutant DNA were generated by PCR using pcDNA3-GSK3␤ constructs as the template, and ligated into pLNCX2. Lentiviral PKC␣, PKC␤ 1, and PKD short hairpin (sh)RNA plasmids were constructed using lentiviral shRNA expression vector, FSIPPW. GSK3␤ shRNA plasmids were purchased from Open Biosystem.
Generation of Stable Knockdown and Overexpression Cells
To generate lentiviruses, PKC␣, PKC␤1, PKD, GSK3␤ shRNA plasmids, or control shRNA plasmids were transfected into 293TD cells with the expression plasmids for packaging (⌬8.9) and envelope (VSVG), and medium was changed the next day. After 24 h, viral supernatants were harvested and new medium was added. Viral supernatants were collected again after 24 h. Viral supernatants were concentrated with Lenti-X concentrator (Clontech), and endothelial cells were infected in the presence of a serum-containing medium supplemented with 8 g/ml polybrene. Virus-containing medium was removed next day, and cells were grown in serum-containing medium for 24 h. Cells were treated with 1 g/ml puromycin, and cells that stably expressed shRNA were selected. The level of target protein expression was determined by immunoblot analysis. For stable overexpression of GSK3␤, the same method was used except pLNCX2-GSK3␤ plasmids, retroviral packaging, envelope plasmids, and Retro-X concentrator (Clontech) were used and selected with G418.
Migration Assay
HUVEC were pretreated with DMSO or GSK-3 inhibitors for 2 h. Cells were then trypsinized and washed with serum-free EBM-2 media containing 0.5% BSA. Cells were resuspended in the same media, and cell number was counted. EBM-2 media containing 5% FBS was added to the bottom chamber of cell-culture inserts (BD Biosciences, 8-m pore size). Cells (4 ϫ 10 4 /100 l) were then added to the top chamber of the cell-culture inserts and incubated for 5 h. The cells that had invaded the lower surface of the membrane were fixed with methanol and stained with 0.2% crystal violet in 2% ethanol. The number of cells that had migrated was quantified by using a light microscope and counting 10 distinct randomly selected fields.
Two-Dimensional Tube-Formation Assay
HUVEC were grown to confluence in EBM-2 endothelial cell growth media supplemented with EGM-2 SingleQuot kit (Lonza). After the media were changed with 2% serum-containing EBM-2, cells were incubated for 18 h. Acid-solubilized collagen I was neutralized and made isotonic according to the manufacturer's instruction and diluted to 500 g/ml with EBM-2. Culture media were gently replaced with the collagen solution, and cells were incubated at 37°C. Tube formation was visualized by light microscopy. To quantify the tube formation, branch points were counted in 5-10 randomly selected microscopic fields per sample and the values averaged. Total tube length was measured using Motic Image Plus.
Three-Dimensional Tube-Formation Assay
The tube morphogenesis assay in three-dimensional (3D) collagen matrix was previously described in detail (24) . Briefly, endothelial cells were suspended in type I collagen matrixes. The mixture was then added to 96-well plates. After collagen polymerization, cells were maintained in M199 media supplemented with growth factors and other supplements. To quantify the tube formation, lumenal area was measured in 10 microscopic fields per sample using Motic Image Plus and normalized to the control. For immunoblot analysis, cells were lysed as described previously (24) .
Immunoblot Analysis
For immunoblot analysis, the cells were extracted in lysis buffer A (20 mM HEPES pH 7.5, 1% Triton X-100, 150 mM NaCl, 10 mM EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM NaF, 2 mM phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin, 2 mg/ml leupeptin, and 1mg/ml pepstatin), and samples were resuspended in reducing buffer (6ϫ: 60 mM Tris·HCl pH 6.8, 25% glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol, and 0.1% bromophenol blue). Samples were boiled for 5 min and electrophoresed by SDS-PAGE. Proteins were then transferred to nitrocellulose membranes (Whatman). The membranes were blocked with TBST (25 mM Tris·HCl pH 7.5, 150 mM NaCl, and 0.05% Tween 20) containing 5% nonfat dried milk or 5% BSA and probed overnight with primary antibodies, followed by 1-h incubation with secondary antibodies coupled to peroxidase. Blots were developed using enhanced chemiluminescence.
Cell Death Assays
Detection of annexin V. Cells were washed once with serumcontaining medium, once with PBS, once with annexin V-FITC buffer (10 mmol/l HEPES-NaOH pH 7.4, 140 mmol/l NaCl, and 2.5 mmol/l CaCl 2), and then incubated for 15 min at room temperature with 5 g/ml annexin V-FITC (Biosource International). After being washed once with annexin V buffer, the samples were resuspended in the same buffer. Immediately before analysis, 5 g/ml propidium iodide (Sigma) were added to distinguish apoptotic cells from necrotic cells and the cells were analyzed using a flow cytometer.
Detection of DNA fragmentation. The sub-G 1 cell population was measured using flow cytometry as described previously (6) . Briefly, cells were fixed with ethanol and washed with PBS. Cells were incubated with propidium iodide, and cell cycle analysis was performed by flow cytometry.
Analysis of Cell-Surface Protein Expression
Cells were trypsinized and washed twice with ice-cold PBS containing 0.2% BSA. Aliquots of cells were incubated for 1 h at 4°C with primary antibodies in the PBS/BSA solution. The cells were washed three times with PBS/BSA and then incubated with secondary antibodies coupled to R-phycoerythrin for 1 h at 4°C. After three washes with PBS/BSA, the cells were resuspended in PBS and analyzed by using a FACScan (Becton Dickinson).
Protein Phosphotransferase Assays
For the PKD kinase assay, HEK293 cells were transfected with pcDNA3-GSK3␤-HA plasmids. Cells were lysed with buffer A containing 1% Triton X-100, and immunoprecipitation was performed using immobilized HA antibody on a Sepharose matrix (Covance). Beads were washed twice in lysis buffer and three times in calf intestinal phosphatase buffer (NEB) and incubated with calf intestinal phosphatase (NEB) for 1.5 h at 37°C. Beads were then washed three times with PKD reaction buffer (50 mM Tris·HCl pH 7.4, 10 mM MgCl 2, and 2 mM dithiothreitol). Kinase assays were performed for 1 h at 30°C with recombinant PKD (Echelon) and immunoprecipitated HA-GSK3␤ as the substrate in PKD reaction buffer containing 500 M ATP. The reaction products were subjected to SDS-PAGE, and immunoblot analysis was performed using anti-phospho-S9 GSK3␤ antibody.
Indirect Immunofluorescence Microscopy
Endothelial cells were plated on cover glasses and incubated with 5% CO 2 at 37°C. The cells were fixed with acetone for 10 min at Ϫ20°C or fixed with 2% paraformaldehyde for 10 min at room temperature. The cells were rinsed with PBS four times and incubated with a blocking solution containing 3% BSA and 5% serum in PBS for 15 min. The cells were then incubated with specific antibodies in blocking solution for 6 h. The cells were rinsed four times and incubated with a secondary antibody conjugated to a fluorochrome (minimal cross-reaction inter-species; Jack- Where applicable, data represent the means Ϯ SE of 3 independent experiments performed in triplicate. Results were statistically significant (*P Ͻ 0.01) using Student's t-test. A and B: migration assay was performed in the presence of GSK3 inhibitors (A), SB216763 and SB415286, or with stable control and GSK3␤ knockdown cells (B). C: stable GSK3␤-WT, GSK3␤-S9A (constitutively active), and GSK3␤-K85A (catalytically inactive) cells were generated as described in MATERIALS AND METHODS. Cells were lysed, and immunoblot analysis was performed. D: migration assay was performed using stable GSK3␤-wild type (WT) and mutant cells. E and F: cell death rate was assessed using the annexin-FITC method (E) or measuring the sub-G1 cell population (F) as described in MATERIALS AND METHODS.
son ImmunoResearch Laboratories) in blocking buffer for 1 h. Cells were rinsed with PBS four times and incubated with DAPI solution (DNA staining) for 15 min. After being washed with PBS four times, cells were mounted with mounting buffer [1% propylgallate in a mixture of glycerol and PBS (8:2)] and examined using a confocal microscope.
RESULTS
GSK-3␤ regulates endothelial cell migration.
As endothelial cell migration plays an essential role in tube morphogenesis, we were curious to see if GSK3␤ regulated migration of these cells. Where applicable, data represent the means Ϯ SE of 3 independent experiments performed in triplicate. Results were statistically significant (*P Ͻ 0.01) using Student's t-test. A: tube-formation assay was performed for 6 h using stable GSK3␤-WT and mutant cells. Scale bar ϭ 100 m. To quantify tube formation, branch points and total tube length were measured in 5-10 random view fields per sample and the values were averaged. B: tube-formation assay was performed with stable control or GSK3␤ knockdown cells for 3 days in three-dimensional (3D) collagen gels. Scale bar ϭ 100 m. C: tube-formation assay was performed for 2 days using stable GSK3␤-WT and mutant cells in 3D collagen gels. Scale bar ϭ 100 m.
We first used specific GSK3 inhibitors, SB415286 and SB216763, and measured endothelial cell migration. As shown in Fig. 1A , both inhibitors increased cell migration. We next knocked down GSK3␤ to determine the function of GSK3␤ in cell migration. As shown in Fig. 1B , knockdown of GSK3␤ increased endothelial cell migration. Unlike other kinases, the unphosphorylated form of GSK3␤ is active in cells and becomes inactive by phosphorylation at the serine 9 (Ser 9) residue upon stimulation by agents such as insulin. We generated stable endothelial cells that expressed wild-type GSK3␤ (GSK3␤-WT), a constitutively active mutant of GSK3␤ (GSK3␤-S9A), or a catalytically inactive mutant of GSK3␤ (GSK3␤-K85A; Fig. 1C ). Using these cells, we performed in vitro migration assays. As shown in Fig. 1D , wild-type GSK3␤ and constitutively active GSK3␤-S9A decreased endothelial cell migration. However, catalytically inactive GSK3␤-K85A increased cell migration. This result suggested that GSK3␤ negatively regulates endothelial cell migration. To examine the possibility that the reduced migration of wild-type GSK3␤ and constitutively active S9A GSK3␤ cells might be due to cell death, we measured cell death rates with an annexin V assay. As shown in Fig. 1E , cell death rates were not different in the different cell types. We confirmed this by measuring the sub-G 1 cell population that represents DNA fragmentation (Fig. 1F ). All together, these results suggest that inhibition of GSK-3␤ increases endothelial cell migration. Collagen I induces tube formation through a GSK3␤-dependent pathway. Since endothelial cell migration is an essential step for endothelial morphogenesis, and exposure of endothelial cells to collagen I plays a key role in endothelial cell morphogenesis and migration, we hypothesized that GSK3␤ might contribute to collagen I-induced tube morphogenesis. Using the GSK3␤ overexpressing cells, we performed collagen I-induced tube-formation assays. As shown in Fig. 2A , vector control cells responded to collagen I by retracting and realigning into cord-like structures. Wild-type or GSK3␤-S9A expressing cells suppressed the morphological changes provoked by collagen I. However, cells expressing catalytically inactive GSK3␤-K85A showed tube formation in response to collagen I. This suggests that GSK3␤ is involved in collagen I-induced tube morphogenesis. Endothelial morphogenesis in an in vitro 3D collagen matrix mimics in vivo vascular morphogenesis (24) . In a 3D collagen system, endothelial cells form and coalesce intracellular vacuoles and lumens, followed by assembly of endothelial cells and formation of tube networks (9) . Therefore, we used a 3D collagen system to determine the function of GSK3␤ in tube formation. As shown in Fig.  2B , control and GSK3␤ knockdown cells formed elaborating tube networks. However, the tube-formation process was faster in the GSK3␤ knockdown cells compared with control. We also examined the function of GSK3␤ overexpression in tube formation in a 3D system. As shown in Fig. 2C , wild-type or GSK3␤-S9A expressing cells suppressed the morphological transition to the network of cords. However, control cells or cells expressing catalytically inactive GSK3␤-K85A arranged into lumencontaining tube networks. Taken together, these results suggest that GSK3␤ regulates endothelial morphogenesis in twodimensional (2D) and 3D culture systems.
Having determined that GSK3␤ regulated endothelial morphogenesis by collagen, we were interested in the relationship between collagen I and GSK3␤ activity. As phosphorylation of GSK3␤ at the Ser 9 residue inactivates this kinase, we determined whether collagen I changed GSK3␤ phosphorylation by using a specific antibody that detects this phosphorylation. As shown in Fig. 3A , collagen I overlay increased GSK3␤ phosphorylation, which indicated that collagen I inhibits GSK3␤ activity. Recently, it was shown that Wnt signaling triggers the sequestration of GSK3 from the cytosol into multivesicular bodies, which regulates GSK3 activity (36) . To determine whether collagen I changes GSK3 activity through regulation of localization, we examined the intracellular localization of GSK3␤. As shown in Fig. 3B , collagen I did not change the localization of GSK3␤. Although there was no change of GSK3␤ localization by collagen I, our results suggested that inactivation of GSK3␤ is an important step in collagen I-induced morphogenesis.
Conventional Pathways That Regulate GSK3 Are Not Involved in Collagen I-Induced Tube Formation
We were then interested in identifying the molecules acting upstream of GSK3␤ in this process. Given that Akt, ERKs, and 
DMSO PD184352
Relative branch points Total tube length 2D total tube length 3D normalized luminal area Fig. 4 . Known upstream regulators of GSK3␤ are not involved in collagen I-induced formation of cords. Where applicable, data represent the means Ϯ SE of 3 independent experiments performed in triplicate. Results were statistically significant (*P Ͻ 0.01) using Student's t-test. A: cells were treated with DMSO, 3 M Go6976, 10 M LY294002, 10 M U0126, or 20 ng/ml rapamycin for 1.5 h, and a tube-formation assay was performed for 20 min. Cells were lysed, and immunoblot analysis was performed. B: cells were treated with DMSO, 3 M Go6976, 10 M LY294002, 10 M U0126, or 20 ng/ml rapamycin for 1.5 h, and a tube-formation assay was performed for 6 h. Scale bar ϭ 100 m. To quantify tube formation, branch points and total tube length were measured in 5-10 random view fields per sample and the values were averaged. C: tube-formation assay was performed in a two-dimensional (2D) or 3D culture system in the absence or presence of 5 M PD184352, a MEK/ERK pathway inhibitor. Scale bar ϭ 100 m. For immunoblot analysis, cells in a 3D collagen system were lysed, and phospho-ERK and total ERK levels were determined. Where applicable, data represent the means Ϯ SE of 3 independent experiments performed in triplicate. Results were statistically significant (*P Ͻ 0.01) using Student's t-test. A: cells were treated with Go6976 for 1.5 h and were subjected to tube-formation conditions for 6 h. Scale bar ϭ 100 m. To quantify tube formation, branch points and total tube length were measured in 5-10 random view fields per sample and the values were averaged. B: stable PKC␣, PKC␤1, and PKD shRNA cells were generated as described in MATERIALS AND METHODS. Expression levels of these proteins were detected by immunoblot analysis. C: tube-formation assay was performed using stable PKC␣, PKC␤1, and PKD knockdown cells. Scale bar ϭ 100 m. To quantify tube formation, branch points and total tube length were measured in 5-10 random view fields per sample and the values were averaged. D: tube-formation assay was performed using stable PKD knockdown cells in a 3D collagen system. Scale bar ϭ 100 m. E: after generating stable PKC␣, PKC␤1, and PKD-knockdown cells, a migration assay was performed as described in MATERIALS AND METHODS.
70-kDa ribosomal S6 kinase (S6K1) negatively regulate GSK3␤ in different cellular contexts (7, 34, 43) , we asked which pathways and what extent of activation of the pathways are required for collagen I-induced tube formation through GSK3␤. We first examined Akt, a downstream target of phosphatidylinositol 3-kinase. Although collagen I increased Akt phosphorylation, LY294002, a phosphatidylinositol 3-kinase/ Akt pathway inhibitor, did not appreciably reduce collagen I-induced GSK3␤ phosphorylation (Fig. 4A) . Moreover, LY294002 treatment had no apparent inhibitory effect on morphological changes induced by collagen I. (Fig. 4B) . We next investigated if ERK and S6K1 were required for collageninduced GSK3␤ phosphorylation and tube formation. Collagen I overlay increased phosphorylation of ERK and S6K1 (Fig. 4A) . However, neither U0126 (a MEK/ERK pathway inhibitor) nor rapamycin (an mammalian target of rapamycin/S6K1 pathway inhibitor) profoundly blocked collagen I-induced GSK3␤ phosphorylation or cord formation (Fig. 4, A and B) . The involvement of the ERK pathway in a 3D collagen system is controversial. Some have reported that this pathway may not be essential for endothelial tube assembly (27) and the ability of the cells to differentiate into tubular structures is not affected by ERK inhibition (26) . However, other reports suggest that inhibition of the ERK pathway suppressed endothelial tube formation (2) and does so by inducing cell death (41) . To determine the role of the ERK pathway in tube formation further, we used a different MEK/ERK inhibitor, PD184352. As shown in Fig. 4C , tube formation in a 2D system was not significantly affected by this inhibitor. We also examined the effect of this inhibitor in a 3D collagen system. As shown in Fig. 4C , tube formation was somewhat inhibited but not profoundly affected by this inhibitor although phospho-ERK levels were decreased dramatically. Since it is known that inhibition of ERK blocks endothelial cell tube formation in a 3D collagen matrix by inducing cell death (41), we used higher concentration of PD184352 and found that it induced cell death that resulted in profound inhibition of vascular morphogenesis in a 3D system (data not shown). Therefore, it seems that under the concentration where the MEK inhibitor could inhibit ERK activity as well as induce cell death, it profoundly blocks tube formation in a 3D system. Taken together, our results suggest that the inhibition of ERK pathway without significant cell death is somewhat involved in collagen-induced tube formation but not profoundly.
Collagen I Induces Endothelial Cell Migration and Cord Formation by a PKD-Dependent Pathway
To determine which signaling pathway was necessary for collagen-induced tube morphogenesis, we screened a number of kinase inhibitors and found that Go6976 (a PKC inhibitor) blocked collagen I-induced tube morphogenesis (Figs. 4, A and  B, and 5A ). Low concentration of Go6976 (1 M) inhibited cord-like structures, and the inhibitory effect was much stronger at higher concentration (3 M; Fig. 5A ). It is known that Go6976 inhibits PKC␣, PKC␤, and PKC (PKD; Ref. 16 ). Thus our data suggested that these kinases may be critical for collagen I-induced endothelial cell morphogenesis. To further test the function of these PKC isoforms in morphogenesis, we stably knocked down endogenous PKC␣, PKC␤ 1 , or PKD using lentiviral shRNA constructs. As shown in Fig. 5B , the knockdown efficiency of PKC␣, PKC␤, and PKD shRNA was Ͼ70%. Tube-formation assays were performed using these stable cells. As shown in Fig. 5C , a cord-like structure was formed by collagen I in PKC␣ or PKC␤1 knockdown cells. In contrast, collagen I did not provoke morphogenesis of PKD knockdown cells. We further studied the function of PKD in tube morphogenesis in a 3D system. For this, PKD knockdown cells were suspended in 3D collagen matrixes and were allowed to undergo tube morphogenesis for 2 days. As shown in Fig. 5D , PKD knockdown impaired endothelial cell morphogenesis into cords and network structures. As endothelial morphogenesis requires endothelial cell migration, we asked whether this process was also regulated by PKD. As shown in Fig. 5E , PKD knockdown cells demonstrated decreased migration compared with control cells. Taken together, our results suggested that PKD plays a key role in collagen I-induced cord formation and migration.
PKD Regulates GSK3␤ in Collagen-Induced Tube Formation
Based on our findings that PKD and GSK3␤ are both required for cord formation induced by collagen I, we next investigated their relationship to each other. As shown in Fig. 6A , phosphor- B: tube-formation assay was performed for 20 min using stable PKD shRNA cells, after which cells were analyzed by immunoblotting. C: in vitro phosphotransferase assays were performed using recombinant PKD (Echelon) and immunopurified HA-GSK3␤ as described in MATERIALS AND METHODS. S9 phosphorylation was measured by immunoblot analysis.
ylated forms of PKD and GSK3␤ were increased by collagen I. This suggested that collagen I increases the activity of PKD but inhibits GSK3␤ activity. We next assessed the possibility that inhibition of GSK3␤ by collagen is dependent on PKD. For this experiment, we used PKD knockdown cells and measured changes in GSK3␤ phosphorylation induced by collagen I. Compared with control, PKD knockdown inhibited GSK3␤ phosphorylation by collagen I (Fig. 6B) . Overall, these results suggested that PKD regulates GSK3␤ in collagen I-induced cord formation. It is known that PKD can phosphorylate serine/threonine residues within a RXXS/T motif. GSK3␤ contains a 6 RTTS 9 sequence, and phosphorylation at S9 determines GSK3␤ activity. Therefore, we determined if PKD directly phosphorylates GSK3␤ at S9 residue. For this, we performed an in vitro kinase assay using recombinant PKD and immunopurified GSK3␤, and examined phosphorylation of GSK3␤ at S9. As shown in Fig. 6C , PKD increased S9 phosphorylation. This suggested that PKD can directly phosphorylate GSK3␤ at the S9 residue in vitro. Taken together, these results indicate that a PKD-dependent pathway positively regulates GSK3␤ phosphorylation and, in so doing, negatively regulates GSK3␤ activity during morphogenesis induced by collagen type I.
GSK3␤ Regulates the Cell-Surface Level of Integrin ␣2␤1
Next, we determined how GSK3␤ regulated collagen I-induced tube formation. Integrins are receptors for extracellular matrix molecules (i.e., collagen and laminin) and critical to cell migration. Since endothelial morphogenesis is highly dependent on endothelial cell migration, we questioned whether there was a link between GSK3␤ and integrins during morphogenesis. To find out which integrins could be necessary for collagen I-induced tube formation, cells were pretreated with function-blocking integrin antibodies (39) and tube-formation assays were performed. As shown in Fig. 7A , antibodies against integrin ␣ 1 (collagen, laminin), ␣ v ␤ 3 (fibronectin, vitronectin, collagen), ␣ 6 (laminin), and ␤ 4 (laminin) failed to block phenotypic changes induced by collagen I. However, an integrin ␣ 2 (collagen, laminin) antibody significantly blocked collagen I-induced endothelial cell alignment into cords. We also used a 3D collagen system to determine the function of Results were statistically significant (*P Ͻ 0.01) using Student's t-test. A: cells were pretreated with 10 g/ml function-blocking anti-integrin antibodies for 1 h, and a tube-formation assay was performed for 6 h. Scale bar ϭ 100 m. B: cells were grown in the presence or absence of 20 g/ml function-blocking anti-integrin ␣2 antibody for 2 days in a 3D system. Scale bar ϭ 100 m.
integrin ␣ 2 and found that blocking the function of this integrin interfered with endothelial cell lumen and tube formation (Fig. 7B) . We then asked whether GSK3␤ regulates the expression of integrin ␣ 2 . Treatment with a specific inhibitor of GSK3␤, SB415286, did not result in a change in integrin ␣ 2 expression (Fig. 8A) nor did the expression of wild-type, constitutively active GSK3␤-S9A, or catalytically inactive GSK3␤-K85A (Fig. 8B) . As integrins that are in the plasma membrane play an important role in cell-matrix attachment and cell migration, we examined cell-surface levels of integrin ␣ 2 using flow cytometry. Of interest, we found that a specific inhibitor of GSK3␤ increased cell surface integrin ␣ 2 ␤ 1 (Fig. 8C ) without changing integrin ␣ 1 ␤ 1 levels (Fig. 8D) . Catalytically inactive GSK3␤-K85A also increased cell-surface integrin ␣ 2 ␤ 1 (Fig. 8E) .
However, integrin ␣ 1 ␤ 1 level was not appreciably changed by GSK3␤ expression (Fig. 8F) . These results suggested that GSK3␤ regulates collagen I-induced cord formation through the modulation of integrin ␣ 2 trafficking.
PKD/GSK3␤ Regulates Trafficking of Integrin
We showed that PKD regulates GSK3␤ activity and that GSK3␤ modulates cell-surface levels of integrin ␣ 2 ␤ 1 . We next investigated if PKD could regulate integrin ␣ 2 ␤ 1 . We used immunoblot analysis to measure total cellular integrin ␣ 2 expression in the stable cells expressing PKD shRNA. As shown in Fig. 9A , these cells all expressed a similar amount of this integrin. As GSK3␤ specifically regulated cell-surface levels of integrin ␣ 2 ␤ 1 , we measured ␣ 2 ␤ 1 using flow cytom- etry. PKD knockdown cells exhibited a marked decrease in cell-surface integrin ␣ 2 ␤ 1 levels (Fig. 9B) . To find out if the change in cell-surface integrin ␣ 2 ␤ 1 induced by PKD was dependent on GSK3␤, PKD knockdown cells were treated with SB415286 and flow cytometry was performed. Treatment of PKD knockdown cells with SB415286 increased cell-surface integrin ␣ 2 ␤ 1 (Fig. 9B) . Altogether, our results indicated that the PKD/GSK3␤/integrin ␣ 2 ␤ 1 pathway is required for collagen I-induced endothelial morphogenesis.
GSK3␤ Regulates the Cell-Surface Level of Integrin
To determine the molecular mechanism by which GSK3␤ inhibition increased cell surface integrin ␣ 2 ␤ 1 , we first examined the localization of this integrin in cells by immunofluorescence. As shown in Fig. 10A , integrin ␣ 2 ␤ 1 was concentrated at the perinuclear regions in untreated control cells, while GSK3 inhibitor-treated cells exhibited dispersed integrin ␣ 2 ␤ 1 in the cytoplasm and more cell surface integrin ␣ 2 ␤ 1 . GSK3␤ regulates the level of some integrins on plasma membrane through modulation of Rab11 (32) . Rab11 is a small GTPase that is involved in recycling of endosomes from the perinuclear region to plasma membrane. Therefore, we hypothesized that GSK3␤ might regulate recycling of integrin ␣ 2 ␤ 1 through Rab11. To test this hypothesis, we examined the localization of integrin ␣ 2 ␤ 1 and Rab11 in the presence or absence of a GSK3 inhibitor. In control cells, Rab11 and integrin ␣ 2 ␤ 1 were primarily found in the perinuclear region and relatively little Rab11 or integrin ␣ 2 ␤ 1 were present near the plasma membrane or dispersed throughout the cytoplasm (Fig. 10A ). GSK3 inhibition, however, caused Rab11-containing vesicles to disperse throughout the cytoplasm and more integrin ␣ 2 ␤ 1 to appear on the plasma membrane. These findings are consistent with the notion that GSK3 inhibition stimulates the ability of Rab11 to mediate the transport of vesicles to the plasma membrane. To further examine the relationship between integrin ␣ 2 ␤ 1 and Rab11, we stably expressed a dominant-negative Rab11, GDP-locked Rab11 (Rab11-S25N) in endothelial cells. Expression of this inactive Rab11 prevented the GSK3 inhibition-induced increase in integrin ␣ 2 ␤ 1 cell surface expression (Fig. 10B) . We next investigated total and cell surface integrin ␣ 2 ␤ 1 levels using immunoblot analysis and flow cytometry, respectively. As shown in Fig. 10 , C and D, GSK-3 inhibition did not appreciably increase total and cell surface integrin ␣ 2 ␤ 1 levels in GDP-locked Rab11 expressing cells. Taken together, our studies suggested that GSK3 inhibition stimulates collagen I-induced tube formation by promoting Rab11 trafficking of the ␣ 2 ␤ 1 integrin.
DISCUSSION
Because vascular morphogenesis is important for both physiological (development, wound healing and reproduction) and pathological (cardiovascular disease, cancer, skin disease, blindness, and diabetic ulcers) processes, comprehensive understanding of the basic processes of blood vessel development and remodeling is essential. Here we report that one of the potent proangiogenic factors, collagen I, induces endothelial cell migration and endothelial morphogenesis through inhibition of GSK3␤. Further studies revealed that GSK3␤ was negatively regulated by PKD, which modulated trafficking of integrin ␣ 2 ␤ 1 .
GSK3␤ regulates a wide range of cellular functions, including metabolism, cytoskeletal integrity, gene expression, cell cycle regulation, and cell survival. Here we present another function of GSK3␤: regulation of tube formation through modulation of integrin ␣ 2 ␤ 1 . Certain integrin heterodimers are internalized from the plasma membrane into endosomal compartments and then recycled back to the cell surface (5) . Trafficking of integrins is important in the regulation of integrin-mediated processes such as cell migration, which can be blocked by inhibition of recycling (22, 32, 40) . Endosomal trafficking and recycling are dependent on microtubules, which endosomes bind and use as "tracks" to guide their movement. GSK3␤ is a well-known regulator of microtubule architecture and dynamics; it acts by phosphorylating a number of microtubule-associated proteins, such as microtubule-associated protein 2C (MAP2C), microtubule-associated protein 1B, tau, adenomatous polyposis coli, and cytoplasmic linker proteinassociating protein 2 (3). GSK3␤ regulates the recycling of integrins ␣ 5 ␤ 1 , ␣ 6 ␤ 4 , and ␣ v ␤ 3 (31) (32) . Little is known about the trafficking of integrin ␣ 2 ␤ 1 . Here we reveal that GSK3␤ regulates trafficking of integrin ␣ 2 ␤ 1 in endothelial cells through Rab11 without affecting the total cellular levels of this integrin. Taken together, it appears that GSK3␤ may be a central regulator of integrin trafficking related to cell migration. As GSK3␤ is involved in diverse cellular processes, regulation of its activity is critical. Phosphorylation of the Ser 9 residue of GSK3␤ results in inactivation of this protein. Several kinases have been found to phosphorylate Ser 9 of GSK3␤ in the context of specific signaling pathways. This residue can be phosphorylated by Akt/PKB during insulin signaling (7) . S6K1 phosphorylates GSK3␤ in response to stimulation by insulin and other growth factors under conditions in which growth factor stimulation of Akt is attenuated (43) . Considering the important roles of GSK3␤ in metabolism, cytoskeletal integrity, gene expression, cell cycle regulation, and cell survival, it is not surprising that regulation of GSK3␤ is complicated and dependent on cellular context. Here we show that PKD can regulate GSK3␤ during collagen I-induced cord formation. PKD, also called PKC, is a novel member of the PKC family. PKD plays a role in cell survival and proliferation by regulating vesicle transport, transcription, and mitochondrial signaling to the nucleus (1, 35) . PKD-mediated signaling pathways in the cardiovascular system, particularly in the regulation of myocardial contraction, hypertrophy, and remodeling are receiving much attention (1). However, not much is known about the function of PKD in endothelial cells. Recently, it was reported that PKD-dependent nuclear export of histone deacetylase-5-mediated VEGF-induced angiogenesis (17) . Here we report on a novel function for PKD in endothelial cell morphogenesis: the regulation of GSK3␤ activity and integrin ␣ 2 ␤ 1 trafficking. As endothelial cell migration is an essential step in endothelial morphogenesis, and because GSK3␤ and integrins are involved in cell migration, it is likely that PKD regulates tube morphogenesis by positively regulating endothelial cell migration. Consistent with this, we found that knockdown of PKD in endothelial cells markedly reduced in vitro cell migration. Ha et al. (17) showed that PKD is also important for VEGFinduced endothelial migration. However, the function of PKD in cell migration is dependent on cell type. As in endothelial cells, PKD positively regulates fibroblast migration (29, 40) . In contrast, in cancer cells, PKD negatively regulates migration through the regulation of actin (12, 28) . Drugs that target PKD are not currently available; however, they could be beneficial as anti-angiogenic therapies. Conversely, these drugs could increase tumor cell migration, invasion, and metastasis in cancer patients. Interestingly, the function of GSK3␤ in cell migration is also dependent on cell type and cellular context. It has been shown that GSK3␤ positively regulates migration of keratinocytes (25) , HeLa (cervical cancer cell line) (23), kidney epithelial cells (14) , and intestinal epithelial cells (38) . However, GSK3␤ negatively regulates migration of fibroblasts (31), astrocytes (13) , and neurons (11). Our results suggest that GSK3␤ negatively regulates endothelial cell migration and tube formation, which is consistent with other reports that inhibition of GSK3␤ induces angiogenesis (18 -20, 42) . Because of the controversial roles of PKD and GSK3␤ in cell migration, more detailed mechanistic studies will be required on these molecules.
In summary, we have described novel regulatory mechanisms and functions for PKD and GSK3␤ in endothelial cells. Considering the roles of these molecules in cardiovascular disease and cancer, these findings enhance our understanding of these diseases and may contribute to the development of new drugs for treating them.
